Guardant Health
Industry / private company
Location:
Palo Alto, CA, Redwood City, CA,
United States (USA) (US)
ROR: https://ror.org/013z4s422
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis (2026)
Friedl TW, Fasching P, Hartkopf AD, Tesch H, Lorenz R, Heinrich G, Blohmer JU, et al.
Journal article
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact (2025)
Hübner H, Wimberger P, Laakmann E, Ruckhäberle E, Rübner M, Lehle S, Uhrig S, et al.
Journal article